Table 1.

Maternal clinical and laboratory characteristics

		Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	n (%)
Clinical characteristics
Date of admission		Jan 20	Jan 25	Jan 27	Jan 26	Jan 27	Jan 27	Jan 28	Jan 29	Jan 30	··
Age (years)		33	27	40	26	26	26	29	28	34	··
Gestational age on admission		37 weeks, 2 days	38 weeks, 2 day	36 weeks	36 weeks, 2 days	38 weeks,1 day	36 weeks, 3 days	36 weeks, 2 days	38 weeks	39 weeks, 4 days	··
Epidemiological history		Yes (exposure to relevant environment)*	Yes (contact with infected person)	Yes (contact with infected person)	Yes (exposure to relevant environment)*	Yes (exposure to relevant environment)*	Yes (contact with infected person)	Yes (contact with infected person)	Yes (contact with infected person)	Yes (exposure to relevant environment)†	9 (100%)
Other family members affected		No	Yes	Yes	No	No	Yes	No	Yes	No	4 (44%)
Onset to delivery (days)		1	6	4	3	1	4	2	2	7	··
Complications		Influenza	None	Gestational hypertension	Pre-eclampsia	Fetal distress	None	PROM	Fetal distress	PROM	··
Signs and symptoms
	Fever on admission	No	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	7 (78%)
	Post-partum fever	Yes	Yes	Yes	Yes	Yes	No	No	No	Yes	6 (67%)
	Myalgia	No	Yes	No	No	Yes	Yes	No	No	No	3 (33%)
	Malaise	No	No	No	No	Yes	Yes	No	No	No	2 (22%)
	Rigor	No	No	No	No	No	No	No	No	No	0
	Cough	Yes	Yes	Yes	No	No	Yes	No	No	No	4 (44%)
	Dyspnoea	No	No	No	Yes	No	No	No	No	No	1 (11%)
	Sore throat	No	No	No	No	No	Yes	Yes	No	No	2 (22%)
	Diarrhoea	No	No	No	Yes	No	No	No	No	No	1 (11%)
	Chest pain	No	No	No	No	No	No	No	No	No	0
Laboratory characteristics
White blood cell count (×109 cells per L)		6·15	5·07	8·78	7·63	9·34	5·57	10·61	9·96	7·08	··
Low or normal leukocyte count (<9·5×109 cells per L)		Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	7 (78%)
Lymphocyte count (×109 cells per L)		1·59	0·56	0·46	2·83	0·69	0·66	0·87	1·53	1·47	··
Lymphopenia (<109 cells per L)		No	Yes	Yes	No	Yes	Yes	Yes	No	No	5 (56%)
C-reactive protein concentration (mg/L)		20·3	14·4	33·4	3·3	28·2	18·2	NA	6·2	24·9	··
Elevated C-reactive protein (>10 mg/L)		Yes	Yes	Yes	No	Yes	Yes	NA	No	Yes	6 (75%)‡
Elevated ALT (>45 U/L) or AST (>35 U/L)		Yes	No	Yes	Yes	No	No	No	No	No	3 (33%)
ALT (U/L)		2093	9	62	54	18	14	6	16	12	··
AST (U/L)		1263	24	71	76	24	23	15	22	21	··
Confirmatory test done (SARS-CoV-2 quantitative RT-PCR)		Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	9 (100%)
CT evidence of pneumonia
Typical signs of viral infection		Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	8 (89%)
Delivery
Method of delivery		C-section	C-section	C-section	C-section	C-section	C-section	C-section	C-section	C-section	··
Indication for C-section		Severely elevated ALT or AST; COVID-19 pneumonia	Mature; COVID-19 pneumonia	History of C-section (×2); COVID-19 pneumonia	Pre-eclampsia; COVID-19 pneumonia	Fetal distress; COVID-19 pneumonia	History of stillbirth (×2); COVID-19 pneumonia	PROM; COVID-19 pneumonia	Fetal distress; COVID-19 pneumonia	PROM; COVID-19 pneumonia	··
Treatment after delivery
	Oxygen support (nasal cannula)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	9 (100%)
	Antiviral therapy	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	6 (67%)
	Antibiotic therapy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	9 (100%)
	Use of corticosteroid	No	No	No	No	No	No	No	No	No	0

PROM=premature rupture of membrane. NA=not applicable. ALT=alanine transaminase. AST=aspartate transaminase. COVID-19=2019 novel coronavirus disease. C-section=caesarean section. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.

^*Exposure to Hankou, the area in Wuhan where the epidemic was first detected.

^†A university where the patient works, and a gathering of people.

^‡Data missing for one patient.